Sigachi Industries Ltd

- Currently, Sigachi Industries Limited has no long-term debt on its books; existing debt pertains only to working capital. - For upcoming capital expenditure (capex), including the Dahej and CCS facilities, the company may raise funds through equity or debt based on the situation and requirement. - The decision to raise equity or debt will be made by the board; no final decision has been announced yet. - No specific ballpark figure for the overall equity plus debt raise has been shared; announcements will be made at an appropriate time. - The company remains focused on capacity expansion with the Dahej MCC expansion and CCS facility commissioning targeted for Q3 FY27.

- Sigachi Industries is undertaking a capacity expansion at the Dahej SEZ facility: - 12,000 metric tons per annum MCC capacity expansion expected to commission by Q3 FY27. - 1,800 tons CCS disintegrant facility at Dahej SEZ is also progressing, targeting the same Q3 FY27 commissioning. - No long-term debt currently; working capital debt only. - For completion of capex, company may raise equity or debt based on board decisions. - Capex plans also include further projects beyond Dahej, including CCS facility. - Exact equity/debt raise amounts are not finalized; company will announce at appropriate time. - Current total cellulose-based excipient capacity is 18,000 metric tons per annum; post expansion, expected to rise to 30,000 metric tons. - Focus on infrastructure, R&D, quality systems, and compliance to support growth and profitability.

- Sigachi anticipates resumption of normalcy in operations with additional capacities coming online, especially the 12,000 metric tons per annum MCC expansion at Dahej, expected by Q3 FY27. - Total cellulose-based excipient capacity will rise to 30,000 metric tons per annum post expansion. - FY27 is expected to see partial recovery in production and margins, with a more significant improvement from FY28 onwards. - Revenue growth of around 25% was targeted pre-incident; FY27 growth will be impacted but expected to normalize gradually. - The company is confident of consistent and sustainable growth over the next 2-3 years, driven by expansion in excipient capacities, API initiatives, and O&M services. - API revenue from Cystic Fibrosis product is expected to commercialize with INR 250 crore revenue potential after 12 months. - Demand for MCC remains strong; no pricing erosion anticipated. - Production utilization currently at ~70-73%, expected to improve post-capacity addition.

- FY27 is expected to see normalization and growth with the commissioning of expanded capacities at the Dahej facility (12,000 MT capacity), targeting Q3 FY27. - EBITDA margins are anticipated to improve gradually, with double-digit EBITDA expected partly in FY27 and more robust margin expansion from FY28 onward. - Revenue growth had slowed due to the Hyderabad plant incident but is expected to rebound as new capacities come online. - Operating income and profitability are projected to grow at a steady pace post-normalization, with FY28 onwards expected to reflect pre-incident growth rates (~25%). - Strategic focus on capacity expansion, product mix improvement, and operational excellence is set to drive sustainable growth. - The API segment has potential revenue of INR 250 crores from Cystic Fibrosis API after 12 months of R&D commercialization. - Continued investment in R&D, compliance, and infrastructure supports long-term growth and value creation.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Sigachi Industries Limited. However, some relevant points related to business outlook and demand are: - Strong customer demand continues for products, especially MCC and other excipients. - The company is focusing on capacity expansion, with Dahej facility capacity expected to ramp up fully by Q3 FY27. - There is an ongoing transition of production from Hyderabad to Dahej and Jhagadia units. - Management expressed confidence in steady and growing demand without pricing pressure. - The API segment expects commercialization of new products (e.g., Cystic Fibrosis API) potentially contributing INR250 crores revenue after 12 months. - Overall, the company plans a steady growth trajectory supported by expanding capacity and diversified portfolio. No specific numerical details on order book or pending orders are disclosed in the transcript.